Chronic non-cancer pain: Focus on once-daily tramadol formulations

Therapeutics and Clinical Risk Management

Volumn 3, Issue 5, 2007, Pages 819-829

  Coluzzi, Flaminia ^a,b,c   Mattia, Consalvo ^a,b  

^a University Polo Pontino   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c NONE   (Italy)

Author keywords

Chronic non cancer pain; Formulations; Once daily; Pharmacokinetics; Sustained release; Tramadol

Indexed keywords

COCODAMOL; CODEINE; CONTRAMID; CORTICOSTEROID DERIVATIVE; DELTA OPIATE RECEPTOR; DEXTROPROPOXYPHENE; DICLOFENAC; DIHYDROCODEINE; HYDROGENATED CASTOR OIL; HYDROXYPROPYLMETHYLCELLULOSE; KAPPA OPIATE RECEPTOR; LOCAL ANESTHETIC AGENT; MORPHINE; MU OPIATE RECEPTOR; NALOXONE; NARCOTIC ANALGESIC AGENT; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; NORADRENALIN; ONDANSETRON; OPIATE DERIVATIVE; OXYCODONE; PARACETAMOL; PENTAZOCINE; PLACEBO; PROSTAGLANDIN SYNTHASE INHIBITOR; SEROTONIN; TQ 1017; TRAMADOL; ULTRAM ER; UNCLASSIFIED DRUG; UNINDEXED DRUG; YOHIMBINE;

AGITATION; ANALGESIC ACTIVITY; AREA UNDER THE CURVE; BEDTIME DOSAGE; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC NONCANCER PAIN; CHRONIC PAIN; CLINICAL TRIAL; COMA; CONSTIPATION; DIARRHEA; DIZZINESS; DROWSINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MARKETING; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; LOW BACK PAIN; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MORNING DOSAGE; NAUSEA; NEUROPATHIC PAIN; NEUROTOXICITY; OSTEOARTHRITIS; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PROTEIN SYNTHESIS INHIBITION; PRURITUS; RESPIRATION DEPRESSION; RESPIRATORY FAILURE; REVIEW; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; SUSTAINED DRUG RELEASE; TABLET FORMULATION; VOMITING;

EID: 36448987959     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. ACR Guidelines. 2000. Recommendations for the Medical Management of Osteoarthritis of the Hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum, 43:1905-15.
2. Adler L, McDonald C, O'Brien C, et al. 2002. comparison of once-daily tramadol with normal release tramadol in the treatment of pain in osteoarthritis. J Rheumatol, 29:2196-9.
3. APS Guidelines. 2002. American Pain Society guideline for treatment of arthritis pain. J Pain Palliat Care Pharmacother, 16:130-2.
4. Babul N, Noveck R, Chipman H, et al. 2004. Efficacy and safety of extended-release, once-daily tramadol in chronic pain: a randomized 12-week clinical trial in osteoarthritis of the knee. J Pain Symptom Manage, 28:59-71.
5. Biovail Investors Relations [online]. Accessed September, 2006. URL: http://www.biovail.com
6. Bird HA, Hill J, Stratford M. 1995. A double blind cross-over study comparing the analgesic efficacy of tramadol with pent ocine in patients with osteoarthritis. J Drug Dev Clin Pract, 7:81-8.
7. Bodalia B, McDonald CJ, Smith KJ, et al. 2003. A omparison of the pharmacokinetics, clinical efficacy, and tolerabili of once-daily tramadol tablets with normal release tramadol capsules. J Pain Symptom Manage, 25:142-9.
8. [CDC] Centers for Disease Control and Prevention. 1997. Update: Direct and in direct costs of arthritis and other rheumatic conditions - United States [online]. Accessed September, 2006. URL: http://www.cdc.gov
9. Cipherpharma. Product overview, CIP Tramadol [online] Accessed December, 2006. URL: http://www.cipherpharma.com
10. Claxon AJ, Cramer J, Pierce C. 2001. A systematic review of the associations between dose regimens and medication compliance. Clin Ther, 23:1296-310.
11. Close BR. 2005. Tramadol: does it have a role in emergency medicine? Emerg Med Australas, 17:73-83.
12. Desmeules JA, Piguet V, Collart L, et al. 1996. Contibution of monoaminergic modulation to the analgesic effect of tramadol. Br J Clin Pharmacol, 41:7-12.
13. De Witte JL, Schoenmaekers B, Sessler DI, et al. 2001. The analgesic efficacy of tramadol is impaired by concurrent administration of ondansetron. Anesth Analg, 92:1319-21.
14. Frank M, Sturm M, Arnau H, et al. 1999. Quality of life and patient compliance during pain therapy: multicenter study using Tramundin retard [in German]. Fortschr Med, 117:38-9.
15. Gana TJ, Pascual ML, Fleming RR, et al. 2006. Extended-release Tramadol in the treatment of osteoarthritis: a multicenter, randomized, double-blind, placebo-controlled clinical trial. Curr Med Res Opin, 22:1391-401.
16. Gardner JS, Blough D, Drinkard CR, et al. 2000. Tramadol and seizures: a surveillance study in a managed care population. Pharmacotherapy, 20:1223-431.
17. Goodwin JL, Kraemer JJ, Bajwa ZH. 2005. The use of opioids in the treatment of osteoarthritis: when, why, and how? Curr Pain Headache Rep, 9:390-8.
18. Grond S, Sablotzky A. 2004. Clinical pharmacology of Tramadol. Clin Pharmacokinet, 43:879-923.
19. Hernandez-Lopez C, Martinez-Farnos L, Karhu D, et al. 2006. Comparative bioavailability between two Tramadol once-daily oral formulations. Methods Find Exp Clin Pharmacol, 28:373-8.
20. Hogan JE. 1989. Hydroxypropyl methylcellulose sustained release technology. Drug Dev Ind Pharm, 15(27):975-99.
21. Ispas-Szabo P, Ravenelle F, Hassan I, et al. 2000. Structure-properties relationship in cross-linked high-amylose starch for use in controlled drug release. Carbohydr Res, 323:163-75.
22. Jensen EM, Ginsberg F. 1994. Tramadol versus dextropropoxyphene in the treatment of esteoarthritis. Drug Invest, 8:211-18.
23. Kalso E, Allan L, Dellemijn PLI, et al. 2003. Recommendations for using opioids in chronic non-cancer pain. Eur J Pain, 7:381-6.
24. Kalso E, Edwards JE, Moore RA, et al. 2004. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain, 112:372-80.
25. Kalso E, Allan L, Dobrogowsky J, et al. 2005. Do strong opioids have a role in the early management of back pain? Recommendations from a European expert panel. Curr Med Res Opin, 21:1819-28.
26. Keating GM. 2006. Tramadol sustained-release capsules. Drugs, 66:223-30.
27. Klotz U. 2003. Tramadol-the impact of its pharmacokinetic and pharmacodynamic properties on the clinical management of pain. Anzneimittelforschung, 53:681-7.
28. Labopharm [online]. Accessed September, 2006. URL: http://www.labopharm.com
29. Malonne H, Coffiner M, Fontaine D, et al. 2005. Long-term tolerability of tramadol LP, a new once-daily formulation, in patients with osteoarthritis or low back pain. J Clin Pharm Ther, 30:113-20.
30. Malonne H, Coffiner M, Sonet B, et al. 2004. Efficacy and tolerability of sustained-release tramadol in the treatment of symptomatic osteoarthritis of the hip or knee: a multicenter, randomized, double-blind, placebo-controlled study. Clin Ther, 26:1774-82.
31. Malonne H, Sonet B, Streel B, et al. 2003. Pharmacokinetic evaluation of a new oral sustained release dosage form of tramadol. Br J Clin Pharmacol, 57:270-8.
32. Mania C, Coluzzi F. 2006. Once-daily Tramadol in rheumatological pain. Expert Opin Pharmacother, 7:1811-23.
33. Mania C, Coluzzi F. Tramadol. 2005. Focus on musculoskeletal and neuropathic pain. Minerva Anestesiol, 71:565-84.
34. Mania C, Mazzaferro S, Coluzzi F, et al. 2004. Respiratory depression following iatrogenic tramadol overuse in a patient with chronic renal failure. J Headache Pain, 5:137-9.
35. Mongin G, Yakusevich V, Kpe A, et al. 2004. Efficacy and safety assessment of a novel once-daily tablet formulation of Tramadol. Clin Drug Invest, 24:545-58.
36. Nieuwenhuijs D, Bruce J, Drummond GB, et al. 2001. Influence of oral tramadol on the dynamic ventilatory response to carbon dioxide in healthy volunteers. Br J Anaesth, 87:860-5.
37. Pavelka K, Peliskova Z, Stelikova H. 1998. Intraindividual differences in pain relief and functional improvement in osteoarthritis with diclofenac or tramadol. Clin Drug Invest, 16:1-9.
38. Rauck RL, Ruoff GE, Mcmillen JI. 1994. Comparison of tramadol and acetaminophen with codeine for long-term pain management in elderly patients. Curr Aer Res Clin Exp, 55:1417-31.
39. Richter A, Anton SE, Koch P, et al. 2003. The Impact of Reducing Dose Frequency on Health Outcomes. Clin Ther, 25:2307-35.
40. Scott LJ, Perry CM. 2000. Tramadol: a review of its use in periopera-tive pain. Drugs, 60:139-76.
41. Smith KJ, Miller AJ, Nichols TP, et al. 1999. Once-daily Tramadol tablets: linear pharmacokinetics [abstract]. 9th World Congress on Pain in Vienna, Austria, 1999. Seattle: IASP Press, p 336-7.
42. Sorge J, Stadler T. 1997. Comparison of the analgesic efficacy and tolerability of tramadol 100mg sustained-release tablets and tramadol 50 mg capsules for the treatment of chronic low back pain Clin Drug Invest, 14:157-64.
43. Taylor H. 1985. The Nuprin pain report. New York: Louis Harris and Associates.
44. Theraquest Biosciences [online]. Accessed May, 2006. URL: http://www.theraquestinc.com
45. Tiwari SB, Murthy TK, Pai MR, et al. 2003. Controlled release formulation of tramadol hydrochloride using hydro-philic and hydrophobic matrix System. AAPS PharmSciTech, 4:1-6.
46. Warren PM, Taylor JH, Nicholson KE, et al. 2000. Influence of tramadol on the ventilatory response to hypoxia in humans. Br J Anaesth, 85:211-16.
47. Wilder-Smith CH, Hill L, Spargo K, et al. 2001. Treatment of severe pain from osteoarthritis with slow-release tramadol or dihydrocodeine in combination with NSAID's: a randomised study comparing analgesia, antinociception and gastrointestinal effects. Pain, 91:23-31.